Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
About the Human Albumin Market
Albumin-based therapies such as Idelvion (CSL654 rIX-FP) by CSL Behring received marketing approval from the US FDA in March 2016 and from the EMA in May 2016. Apart from these, Albutropin (TV-1106) by Teva Pharmaceuticals, Ampion by Ampio Pharmaceuticals, and Albutein by Grifols (for Alzheimer's disease) are expected to enter the market during the forecast period.
The demand for albumin is high in APAC in countries like India and China. Still, the uptake of these therapeutics is less due to the lack of awareness about these products and their therapeutic uses. Thus, the awareness programs conducted by organizations such as PPTA, which includes International Plasma Awareness Week, to help increase the awareness about plasma donation and the different plasma protein therapies available, along with their potential uses, is expected to increase the uptake of these therapeutics in treating various conditions.
Technavio’s analysts forecast the global human albumin market to grow at a CAGR of 4.97% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global human albumin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic albumin drugs used to treat infections, liver diseases, shock, during surgery, and severe burns. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched in the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Human Albumin Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• CSL Behring
• Grifols
• Baxalta
• Octapharma
• Kedrion
Other prominent vendors
• AADi
• Ablynx
• Albumedix
• Ampio Pharmaceuticals
• Azaya Therapeutics
• Beijing Tiantan
• Biotest
• Bristol-Myers Squibb
• Celgene
• ConjuChem
• GSK
• Hebei Changshan Biochem Pharma
• HiMedia Laboratories
• Hualan Biological Engineering
• InVittria
• MedxBio
• Merck
• Mitsubishi Tanabe Pharma
• NantBioScience
• Novo Nordisk
• Novozymes
• Shanghai RAAS Blood Products
• Sucampo Pharmaceuticals
• Teva Pharmaceuticals
• Thermo Fisher Scientific
• Tianjin SinoBiotech & Beijing Bio-Fortune
• Ventria Bioscience
• Yoshitomi Pharmaceutical
Market driver
• High demand for human albumin in China
• For a full, detailed list, view our report
Market challenge
• Spread of pathogenic contaminants
• For a full, detailed list, view our report
Market trend
• Rise in non-therapeutic applications
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Albumin-based therapies such as Idelvion (CSL654 rIX-FP) by CSL Behring received marketing approval from the US FDA in March 2016 and from the EMA in May 2016. Apart from these, Albutropin (TV-1106) by Teva Pharmaceuticals, Ampion by Ampio Pharmaceuticals, and Albutein by Grifols (for Alzheimer's disease) are expected to enter the market during the forecast period.
The demand for albumin is high in APAC in countries like India and China. Still, the uptake of these therapeutics is less due to the lack of awareness about these products and their therapeutic uses. Thus, the awareness programs conducted by organizations such as PPTA, which includes International Plasma Awareness Week, to help increase the awareness about plasma donation and the different plasma protein therapies available, along with their potential uses, is expected to increase the uptake of these therapeutics in treating various conditions.
Technavio’s analysts forecast the global human albumin market to grow at a CAGR of 4.97% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global human albumin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic albumin drugs used to treat infections, liver diseases, shock, during surgery, and severe burns. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched in the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Human Albumin Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• CSL Behring
• Grifols
• Baxalta
• Octapharma
• Kedrion
Other prominent vendors
• AADi
• Ablynx
• Albumedix
• Ampio Pharmaceuticals
• Azaya Therapeutics
• Beijing Tiantan
• Biotest
• Bristol-Myers Squibb
• Celgene
• ConjuChem
• GSK
• Hebei Changshan Biochem Pharma
• HiMedia Laboratories
• Hualan Biological Engineering
• InVittria
• MedxBio
• Merck
• Mitsubishi Tanabe Pharma
• NantBioScience
• Novo Nordisk
• Novozymes
• Shanghai RAAS Blood Products
• Sucampo Pharmaceuticals
• Teva Pharmaceuticals
• Thermo Fisher Scientific
• Tianjin SinoBiotech & Beijing Bio-Fortune
• Ventria Bioscience
• Yoshitomi Pharmaceutical
Market driver
• High demand for human albumin in China
• For a full, detailed list, view our report
Market challenge
• Spread of pathogenic contaminants
• For a full, detailed list, view our report
Market trend
• Rise in non-therapeutic applications
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
